BIOMEDITECH ApS: Financial statements 2022
CVR: 34707847
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
BIOMEDITECH ApS (CVR 34707847) has filed annual accounts for 2022. In 2022, the company reported revenue of DKK 112,317 and a net result of DKK 105,612 compared with DKK 76,139 the year before. The profit margin was 94%. Equity in the 2022 report amounted to DKK 232,638. The solvency ratio was 88.5%.
- Revenue
- DKK 112,317
- Gross Profit
- DKK 112,003
- Profit/Loss
- DKK 105,612
- Equity
- DKK 232,638
- Total Assets
- DKK 262,921
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 112K | 112K | 106K | 233K | - |
| 2021 | - | - | 76K | 127K | - |
| 2020 | 27K | 27K | 17K | 51K | - |
| 2019 | - | - | -13K | 34K | - |
| 2018 | - | - | -18K | 47K | - |
Official annual report
Keep an eye on BIOMEDITECH ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
BIOMEDITECH ApS has published its annual report for 2021. The net result was DKK 76,139.
About BIOMEDITECH ApS
BIOMEDITECH ApS is a Danish company of the type Anpartsselskab based in Herlev, founded in 2012. The company is registered under the industry Engroshandel med andre maskiner og andet udstyr. The company was previously named DRUG TESTING EUROPE ApS. The management consists of Tobias Chalmer Stahl Rasmussen. The company is owned by Chalmer Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 106,895 and a net result of DKK -6,298 compared with DKK 290,046 the year before. Equity in the 2025 report amounted to DKK 877,884.